The new manufacturing site is a part of an expansion project within Biovest’s 35,000sqft cell culture center in Coon Rapids.
The new expanded facility will manufacture Biovest’s late-stage, autologous, active immunotherapy for the treatment of non-Hodgkin’s lymphoma.
Biovest president Samuel Duffey said this is a key milestone as they are initiating the commissioning and validation processes with the facility currently undergoing comprehensive testing and review to ensure that the BiovaxID manufacturing ‘clean rooms’ are consistent with our standards of operational excellence and will satisfy the regulatory criteria of an FDA inspection.
"Furthermore, I expect we will be producing BiovaxID vaccines in this new facility sometime this summer," Duffey said.